- Home
- MBRX vs BCDA Comparison
MBRX vs BCDA Comparison
Compare MBRX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- BCDA
- Stock Information
- Founded
- MBRX 2015
- BCDA N/A
- Country
- MBRX United States
- BCDA United States
- Employees
- MBRX N/A
- BCDA N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- BCDA Health Care
- Exchange
- MBRX Nasdaq
- BCDA Nasdaq
- Market Cap
- MBRX 11.3M
- BCDA 9.4M
- IPO Year
- MBRX 2016
- BCDA N/A
- Fundamental
- Price
- MBRX $1.11
- BCDA $1.82
- Analyst Decision
- MBRX Strong Buy
- BCDA Strong Buy
- Analyst Count
- MBRX 2
- BCDA 1
- Target Price
- MBRX $6.00
- BCDA $25.00
- AVG Volume (30 Days)
- MBRX 338.4K
- BCDA 92.0K
- Earning Date
- MBRX 05-09-2025
- BCDA 05-13-2025
- Dividend Yield
- MBRX N/A
- BCDA N/A
- EPS Growth
- MBRX N/A
- BCDA N/A
- EPS
- MBRX N/A
- BCDA N/A
- Revenue
- MBRX N/A
- BCDA $58,000.00
- Revenue This Year
- MBRX N/A
- BCDA N/A
- Revenue Next Year
- MBRX N/A
- BCDA N/A
- P/E Ratio
- MBRX N/A
- BCDA N/A
- Revenue Growth
- MBRX N/A
- BCDA N/A
- 52 Week Low
- MBRX $0.40
- BCDA $1.63
- 52 Week High
- MBRX $5.47
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- MBRX 58.77
- BCDA 36.67
- Support Level
- MBRX $0.80
- BCDA $1.73
- Resistance Level
- MBRX $1.05
- BCDA $1.93
- Average True Range (ATR)
- MBRX 0.10
- BCDA 0.14
- MACD
- MBRX 0.04
- BCDA -0.02
- Stochastic Oscillator
- MBRX 100.00
- BCDA 20.24
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).